Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Antidepressant Use Begins Years Before Alzheimer’s Diagnosis

By Drug Discovery Trends Editor | March 7, 2016

Antidepressants are frequently initiated in persons with Alzheimer’s disease already before the diagnosis, shows a recent study from the University of Eastern Finland. Among persons with Alzheimer’s disease, the initiation of antidepressant use was most common during the six months after the Alzheimer’s diagnosis, and more frequent than among comparison persons without Alzheimer’s disease even 4 years after the diagnosis. The results were published in International Journal of Geriatric Psychiatry.

Antidepressant initiation was more frequent among persons with Alzheimer’s disease already 9 years before the diagnosis than among comparison persons not diagnosed with Alzheimer’s disease. This finding was somewhat surprising. It may be related to more frequent treatment of depressive symptoms because depression has been associated with an increased risk of Alzheimer’s disease in previous studies.

Antidepressant use was investigated in the Finnish nationwide MEDALZ study from 9 years before until 4 years after the diagnosis of Alzheimer’s disease. The difference in antidepressant initiations persisted during the entire follow-up period. During the 13-year follow-up period, 42% of persons with Alzheimer’s disease and 22% of persons not diagnosed with the disease initiated antidepressant use. The most commonly used antidepressant group was selective serotonin reuptake inhibitor (SSRI) drugs, followed by mirtazapine.

The register-based study was based on 62,104 Finnish persons with Alzheimer’s disease diagnosed between 2005 and 2011.

Source: University of Eastern Finland


Filed Under: Drug Discovery

 

Related Articles Read More >

Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
Labcorp widens precision oncology toolkit, aims to speed drug-trial enrollment
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE